Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Isoray Inc (ISR)

Isoray Inc (ISR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Isoray Inc 350 HILLS STREET SUITE 106 RICHLAND WA 99354 USA

www.isoray.com P: 509-375-1202

Description:

IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated.

Key Statistics

Overview:

Market Capitalization, $K 54,571
Enterprise Value, $K -1,319
Shares Outstanding, K 142,113
Annual Sales, $ 10,800 K
Annual Net Income, $ -7,270 K
Last Quarter Sales, $ 1,720 K
Last Quarter Net Income, $ -4,070 K
60-Month Beta 1.48
% of Insider Shareholders 2.42%
% of Institutional Shareholders 11.32%
Float, K 138,674
% Float 97.58%
Short Volume Ratio 0.24

Growth:

1-Year Return 4.26%
3-Year Return -55.74%
5-Year Return -16.52%
5-Year Revenue Growth 126.89%
5-Year Earnings Growth 54.55%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.03 on 11/10/22
Next Earnings Date 02/14/23
Earnings Per Share ttm -0.06
EPS Growth vs. Prev Qtr 33.33%
EPS Growth vs. Prev Year -100.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ISR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -17.12%
Return-on-Assets % -16.15%
Profit Margin % -67.31%
Debt/Equity 0.00
Price/Sales 5.05
Price/Cash Flow N/A
Price/Book 0.95
Book Value/Share 0.41
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar